Foghorn Therapeutics Inc (FHTX) - Total Liabilities
Based on the latest financial reports, Foghorn Therapeutics Inc (FHTX) has total liabilities worth $284.43 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Foghorn Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Foghorn Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Foghorn Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Foghorn Therapeutics Inc assets under control.
Foghorn Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Foghorn Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Armada Acquisition Corp. II
NASDAQ:XRPN
|
USA | $255.87 Million |
|
BT Group Plc
LSE:BT-A
|
UK | GBX37.41 Billion |
|
Immersion Corporation
NASDAQ:IMMR
|
USA | $552.01 Million |
|
Halla Holdings Corp
KO:060980
|
Korea | ₩1.27 Trillion |
|
Pacific Smiles Group Ltd
AU:PSQ
|
Australia | AU$104.03 Million |
|
JNK India Ltd
NSE:JNKINDIA
|
India | Rs4.91 Billion |
|
J.G.CHEMICALS LIMITED
NSE:JGCHEM
|
India | Rs282.86 Million |
|
Tianyu Ecology & Landscape Co
SHG:603717
|
China | CN¥2.29 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Foghorn Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See FHTX equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Foghorn Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Foghorn Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Foghorn Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $306.60 Million | -6.95% |
| 2024-12-31 | $329.51 Million | -9.25% |
| 2023-12-31 | $363.11 Million | -10.29% |
| 2022-12-31 | $404.77 Million | -4.29% |
| 2021-12-31 | $422.90 Million | +286.54% |
| 2020-12-31 | $109.41 Million | -0.86% |
| 2019-12-31 | $110.36 Million | +34.04% |
| 2018-12-31 | $82.33 Million | -- |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mu… Read more